The opportunity offered by biosimilars is still unfolding. But the value they can offer is clear - Scott Gottlieb


image by: The Center for Biosimilars

HWN Recommends

The Case For Letting Biosimilars Compete

As policy makers try to address unsustainable prices for biologic drugs, concerns about the fledgling US market for biosimilars have come to the forefront. Some experts have even suggested abandoning biosimilars in favor of more heavy-handed mechanisms to lower the prices of biologics. We agree that there are unique barriers to biosimilar competition. Giving up on the biosimilars market while it is still in its infancy, however, would be a detriment to both patients and the health care system as a whole.

Kaiser Permanente knows from experience that biosimilars have significant value. We successfully use biosimilars to improve affordability for patients, saving our system millions of…

read full article


Related Articles

Stay Connected

©2021 | HealthWorldNet, Inc. | 114741

Last Updated : Thursday, January 7, 2021